Summary
Cancer-associated fibroblasts (CAFs) are one of the most abundant and versatile cell types in the tumour microenvironment (TME), where they crosstalk with stromal cells and actively participate in tumour development. Because of their assumed pro-tumourigenic functions, CAFs have long been considered an attractive therapeutic target. However, recent evidence indicates that multiple CAF subpopulations showing inflammatory, myofibroblastic, vascular, antigen-presenting, and immunosuppressive phenotypes co-exist within the same tumour, – with some promoting and other restricting tumour growth; thus, making their targeting challenging. How CAFs change dynamically as cancers evolve, and how this may affect the overall tumour heterogeneity, remains unaddressed. Therefore, the main goal of DynamHet is to elucidate the origin and evolution of CAF heterogeneity and to decipher the mediators and mechanisms that regulate CAF plasticity as the tumour advances. This is crucial for the development of effective therapies aimed at reprogramming CAFs towards therapeutically favourable phenotypes and will constitute a great breakthrough in the field of oncology. Hence, DynamHet aims to 1) decipher the origin of CAF heterogeneity by performing clonal tracing and by generating and characterising CAF subtypes starting from human induced pluripotent stem cells; 2) dissect CAF-TME crosstalk by generating 3D patient-derived organoids and spheroids and by analysing their secretome and transcriptomic profiles using high throughput technologies and computational analysis; and 3) reprogramme CAFs by genetic manipulation in favour of therapeutically advantageous subpopulations as a novel therapeutic approach. DynamHet is an ambitious and feasible project that stands as a pioneer in the new concept of deciphering the origin and reprogramming the dynamic heterogeneity of CAFs towards the development of innovative precision medicine approaches in cancer.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/101077312 |
| Start date: | 01-09-2023 |
| End date: | 31-08-2028 |
| Total budget - Public funding: | 1 775 190,00 Euro - 1 775 190,00 Euro |
Cordis data
Original description
Cancer-associated fibroblasts (CAFs) are one of the most abundant and versatile cell types in the tumour microenvironment (TME), where they crosstalk with stromal cells and actively participate in tumour development. Because of their assumed pro-tumourigenic functions, CAFs have long been considered an attractive therapeutic target. However, recent evidence indicates that multiple CAF subpopulations showing inflammatory, myofibroblastic, vascular, antigen-presenting, and immunosuppressive phenotypes co-exist within the same tumour, – with some promoting and other restricting tumour growth; thus, making their targeting challenging. How CAFs change dynamically as cancers evolve, and how this may affect the overall tumour heterogeneity, remains unaddressed. Therefore, the main goal of DynamHet is to elucidate the origin and evolution of CAF heterogeneity and to decipher the mediators and mechanisms that regulate CAF plasticity as the tumour advances. This is crucial for the development of effective therapies aimed at reprogramming CAFs towards therapeutically favourable phenotypes and will constitute a great breakthrough in the field of oncology. Hence, DynamHet aims to 1) decipher the origin of CAF heterogeneity by performing clonal tracing and by generating and characterising CAF subtypes starting from human induced pluripotent stem cells; 2) dissect CAF-TME crosstalk by generating 3D patient-derived organoids and spheroids and by analysing their secretome and transcriptomic profiles using high throughput technologies and computational analysis; and 3) reprogramme CAFs by genetic manipulation in favour of therapeutically advantageous subpopulations as a novel therapeutic approach. DynamHet is an ambitious and feasible project that stands as a pioneer in the new concept of deciphering the origin and reprogramming the dynamic heterogeneity of CAFs towards the development of innovative precision medicine approaches in cancer.Status
SIGNEDCall topic
ERC-2022-STGUpdate Date
31-07-2023
Images
No images available.
Geographical location(s)
